Hypertrophy of the Heart: A New Therapeutic Target?

Circulation

Volumn 109, Issue 13, 2004, Pages 1580-1589

  Frey, Norbert ^a   Katus, Hugo A ^a   Olson, Eric N ^b   Hill, Joseph A ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hypertrophy; Signal transduction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE INHIBITORY PEPTIDE; BINDING PROTEIN; CALCINEURIN INHIBITOR; CERIVASTATIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN AKAP70; PROTEIN CABIN; PROTEIN CAIN; SIMVASTATIN; TACROLIMUS; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART FAILURE; HEART HYPERTROPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SHOCK; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ARRHYTHMIA; CALCIUM; CARDIAC OUTPUT; CARDIOVASCULAR AGENTS; CELL SIZE; CLINICAL TRIALS; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ION CHANNELS; MECHANORECEPTORS; MUSCLE PROTEINS; MYOCYTES, CARDIAC; PRESSURE; VENTRICULAR REMODELING;

EID: 1842579393     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000120390.68287.BB     Document Type: Review

References (145)

1. Sandler H, Dodge HT. Left ventricular tension and stress in man. Circ Res. 1963;13:91-104.
2. Hood WP, Rackley CE, Rolett EL. Wall stress in the normal and hypertrophied human left ventricle. Am J Cardiol. 1968;22:550-558.
3. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
4. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
5. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Int Med. 1991;114:345-352.
6. Meerson FZ. On the mechanism of compensatory hyperfunction and insufficiency of the heart. Cor Vasa. 1961;3:161-177.
7. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205.
8. Armoundas AA, Wu R, Juang G, et al. Electrical and structural remodeling of the failing ventricle. Pharmacol Ther. 2001;92:213-230.
9. Hill JA. Electrical remodeling in cardiac hypertrophy. Trends Cardiovasc Med. 2003;13:316-322.
10. Haunstetter A, Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res. 2000;86:371-376.
11. Osler W. The Principles and Practice of Medicine. New York: D. Appleton and Co; 1892.
12. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003;92:1171-1175.
13. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol. 2003;65:45-79.
14. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res. 2003;92:1079-1088.
15. Katz AM. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med. 1990;322:100-110.
16. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998;76:725-746.
17. Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest. 2002;109:849-855.
18. Molkentin JD, Lu J-R, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
19. Leinwand LA. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc Natl Acad Sci U S A. 2001;98:2947-2949.
20. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 1997;12:375-381.
21. Imakita M, Tazelaar HD, Rowan RA, et al. Myocyte hypertrophy in the transplanted heart: a morphometric analysis. Transplantation. 1987;43:839-842.
22. Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell. 2000;101:689-692.
23. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101:2863-2869.
24. Taigen T, De Windt LJ, Lim HW, et al. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2000;97:1196-1201.
25. De Windt LJ, Lim HW, Bueno OF, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3322-3327.
26. Zou Y, Hiroi Y, Uozumi H, et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001;104:97-101.
27. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in calcineurin Abeta-deficient mice. Proc Natl Acad Sci U S A. 2002;99:4586-4591.
28. Rothermel BA, Vega RB, Yang J, et al. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem. 2000;275:8719-8725.
29. Kingsbury TJ, Cunningham KW. A conserved family of calcineurin regulators. Genes Dev. 2000;14:1595-1604.
30. Yang J, Rothermel BA, Vega RB, et al. Independent signals control expression of the calcineurin inhibitory proteins MCIPI and MCIP2 in striated muscles. Circ Res. 2001;87:e61-e68.
31. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIPI, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3328-3333.
32. Hill JA, Rothermel BA, Yoo K-D, et al. Targeted inhibition of calcineurin in pressure-overload hypertrophy: preservation of systolic function. J Biol Chem. 2002;277:10251-10255.
33. Vega RB, Rothermel BA, Weinheimer CJ, et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:669-674.
34. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res. 2003;92:725-731.
35. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206-212.
36. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Cardiac hypertrophy: role of G protein-coupled receptors. J Card Fail. 2002;8:S409-S414.
37. Adams JW, Sakata Y, Davis MG, et al. Enhanced G alpha q signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA. 1998;95:10140-10145.
38. Koch WJ, Lefkowitz RJ, Rockman HA. Functional consequences of altering myocardial adrenergic receptor signaling. Annu Rev Physiol. 2000;62:237-260.
39. Offermanns S, Zhao LP, Gohla A, et al. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha(q)/G alpha(11)-mutant mice. EMBO J. 1998;17:4304-4312.
40. Wettschureck N, Rutten H, Zywietz A, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of G alpha(q)/G alpha(11) in cardiomyocytes. Nat Med. 2001;7:1236-1240.
41. Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998;280:574-577.
42. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
43. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-830.
44. Gaudin C, Ishikawa Y, Wight DC, et al. Overexpression of G(S-alpha) protein in the hearts of transgenic mice. J Clin Invest. 1995;95:1676-1683.
45. Engelhardt S, Hein L, Wiesmann F, et al. Progressive hypertrophy and heart failure in beta(1)-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059-7064.
46. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88-91.
47. Dorn GW, Tepe NM, Lorenz JN, et al. Low- and high-level transgenic expression of beta(2)-adrenergic receptors differentially affect cardiac hypertrophy and function in G alpha q-overexpressing mice. Proc Natl Acad Sci U S A. 1999;96:6400-6405.
48. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA. 1998;95:7000-7005.
49. Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA. 2001;98:5809-5814.
50. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
51. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548.
52. McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase(p110 alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:12355-12360.
53. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737-749.
54. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896-22901.
55. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:12333-12338.
56. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799-2809.
57. Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther. 2002;300:1101-1110.
58. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits alpha(1)-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: evidence for involvement of p70 S6 kinase. Circ Res. 1997;81:176-186.
59. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin-II-induced increase in protein-synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin-II-induced cardiac hypertrophy. Circ Res. 1995;77:1040-1052.
60. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664-1670.
61. Morisco C, Zebrowski D, Condorelli G, et al. The Akt-glycogen synthase kinase 3 beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem. 2000;275:14466-14475.
62. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3 beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000;151:117-129.
63. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002;99:907-909.
64. Morisco C, Seta K, Hardt SE, et al. Glycogen synthase kinase 3 beta regulates GATA4 in cardiac myocytes. J Biol Chem. 2001;276:28586-28597.
65. Kuhn M, Holtwick R, Baba HA, et al. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart. 2002;87:368-374.
66. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA. 2001;98:2703-2706.
67. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003;111:1399-1407.
68. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363-11368.
69. Kolodziejczyk SM, Wang L, Balazsi K, et al. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol. 1999;9:1203-1206.
70. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002;27:40-47.
71. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488.
72. Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest. 2003;112:863-871.
73. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 2002;7:175-185.
74. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238-245.
75. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240-1246.
76. Yamamoto K, Ohki R, Lee RT, et al. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104:1670-1675.
77. Lehman JJ, Barger PM, Kovacs A, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106:847-856.
78. Young ME, Laws FA, Goodwin GW, et al. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276:44390-44395.
79. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPAR alpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-130.
80. Finck BN, Han XL, Courtois M, et al. A critical role for PPAR alpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003;100:1226-1231.
81. Jamshidi Y, Montgomery HE, Hense HW, et al. Peroxisome proliferator-activated receptor a gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105:950-955.
82. Czubryt MP, McAnally J, Fishman GI, et al. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A. 2003;100:1711-1716.
83. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res. 2000;86:1019-1023.
84. Hunter JJ, Tanaka N, Rockman HA, et al. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173-23178.
85. Fuller SJ, Gillespie-Brown J, Sugden PH. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem. 1998;273:18146-18152.
86. Thornburn A. Ras activity is required for phenylephrine-induced activation of mitogen-activated protein kinase in cardiac muscle cells. Biochem Biophys Res Commun. 1994;205:1417-1422.
87. Abdellatif M, Packer SE, Michael LH, et al. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol. 1998;18:6729-6736.
88. Hoshijima M, Sah VP, Wang YB, et al. The low molecular weight GTPase rho regulates myofibril formation and organization in neonatal rat ventricular myocytes: involvement of Rho kinase. J Biol Chem. 1998;273:7725-7730.
89. Charron F, Tsimiklis G, Areand M, et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 2001;15:2702-2719.
90. Sah VP, Hoshijima M, Chien KR, et al. Rho is required for G alpha(q) and alpha(1)-adrenergic receptor signaling in cardiomyocytes: dissociation of Ras and Rho pathways. J Biol Chem. 1996;271:31185-31190.
91. Sah VP, Minamisawa S, Tam SP, et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest. 1999;103:1627-1634.
92. Eble DM, Strait JB, Govindarajan G, et al. Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. Am J Physiol Heart Circ Physiol. 2000;278:H1695-H1707.
93. Sussman MA, Welch S, Walker A, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest. 2000;105:875-886.
94. Eble DM, Strait JB, Govindarajan G, et al. Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. Am J Physiol Heart Circ Physiol. 2000;278:H1695-H1707.
95. Taylor JM, Rovin JD, Parsons JT. A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J Biol Chem. 2000;275:19250-19257.
96. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol. 1999;376:139-148.
97. Luo JD, Xie F, Zhang WW, et al. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol. 2001;132:159-164.
98. Luo JD, Zhang WW, Zhang GP, et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol. 1999;26:903-908.
99. Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 2001;104:576-581.
100. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868-873.
101. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317-324.
102. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
103. Laufs U, Kilter H, Konkol C, et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53:911-920.
104. Sadoshima J, Izumo S. The cellular and molecular response to cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551-571.
105. Zou Y, Takano H, Akazawa H, et al. Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. Endocr J. 2002;49:1-13.
106. Brancaccio M, Fratta L, Notte A, et al. Melusin, a muscle-specific integrin beta(1)-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med. 2003;9:68-75.
107. Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111:943-955.
108. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci U S A. 2000;97:14632-14637.
109. Takewaki S, Kuroo M, Hiroi Y, et al. Activation of Na+-H+ antiporter (Nhe-1) gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J Mol Cell Cardiol. 1995;27:729-742.
110. Yoshida H, Karmazyn M. Na+/H+ exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol. 2000;278:H300-H304.
111. Cingolani HE, de Hurtado MCC. Na+-H+ exchanger inhibition: a new antihypertrophic tool. Circ Res. 2002;90:751-753.
112. Kusumoto K, Haist JV, Karmazyn M. Na+/H+ exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2001;280:H738-H745.
113. Engelhardt S, Hein L, Keller U, et al. Inhibition of Na+-H+ exchange prevents hypertrophy, fibrosis, and heart failure in {beta} 1-adrenergic receptor transgenic mice. Circ Res. 2002;90:814-819.
114. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA. 1998;95:7000-7005.
115. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation. 2001;104:1424-1429.
116. 2+-ATPase. Circulation. 2000;101:790-796.
117. 2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;278:33809-33817.
118. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res. 1994;75:401-409.
119. del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105:904-907.
120. Minamisawa S, Hoshijima M, Chu GX, et al. Chronic phospholambansarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313-322.
121. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002;8:864-871.
122. Sato Y, Kiriazis H, Yatani A, et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 2001;276:9392-9399.
123. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001;107:967-974.
124. Song Q, Schmidt AG, Hahn HS, et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest. 2003;111:859-867.
125. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-1413.
126. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-876.
127. Scheuer J, Malhotra A, Hirsch C, et al. Physiological cardiac hypertrophy corrects protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest. 1982;70:1300-1305.
128. Iemitsu M, Miyauchi T, Maeda S, et al. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol. 2001;281:R2029-R2036.
129. Diffee GM, Seversen EA, Stein TD, et al. Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles. Am J Physiol Heart Circ Physiol. 2003;284:H830-H837.
130. Kinugawa K, Yonekura K, Ribeiro RCJ, et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res. 2001;89:591-598.
131. Calderone A, Takahashi N, Izzo NJ Jr, et al. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation. 1995;92:2385-2390.
132. Kjeldsen SE, Dahlöf B, Devereux RB, et al, for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA. 2002;288:1491-1498.
133. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
134. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
135. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published erratum appears in JAMA 2003;289:178]. JAMA. 2002;288:2981-2997.
136. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published erratum appears in JAMA 2003;289:178]. JAMA. 2002;288:2981-2997.
137. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
138. Senbonmatsu T, Ichihara S, Price E, et al. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000;106:R25-R29.
139. G-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation. 2000;101:423-429.
140. Ichihara S, Senbonmatsu T, Price E, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001;104:346-351.
141. Uozumi H, Hiroi Y, Zou Y, et al. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem. 2001;276:23115-23119.
142. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664-1670.
143. Hirota H, Chen J, Betz UAK, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189-198.
144. Rogers JH, Tamirisa P, Kovacs A, et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest. 1999;104:567-576.
145. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest. 2002;109:373-381.